Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study

AIDS. 2002 Dec 6;16(18):2489-91. doi: 10.1097/00002030-200212060-00020.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • HIV-Associated Lipodystrophy Syndrome / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Stavudine / therapeutic use*
  • Substance Withdrawal Syndrome
  • Thymidine / analogs & derivatives*
  • Zidovudine / therapeutic use*

Substances

  • Anti-HIV Agents
  • Zidovudine
  • Stavudine
  • Thymidine